

IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A derivative formed between hyaluronic acid and at least one heterocyclic compound ~~derived~~ selected from purine ~~and/or from or~~ pyrimidine, said derivative ~~being provided with~~ having at least one bond of a ionic type between said acid and said at least one heterocyclic compound.
2. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of high molecular weight.
3. (original) The derivative according to Claim 2, characterized in that said hyaluronic acid has a molecular weight of between 400 000 and 4 million dalton.
4. (original) The derivative according to Claim 3, characterized in that said hyaluronic acid has a molecular weight of between 800 000 and 3.5 million dalton.
5. (original) The derivative according to Claim 4, characterized in that said hyaluronic acid has a molecular weight of between 1.5 and 3 million dalton.
6. (original) The derivative according to Claim 1, characterized in that said hyaluronic acid is hyaluronic acid of low molecular weight.
7. (currently amended) The derivative according to Claim 1, characterized in that said heterocyclic compound is ~~chosen between~~ selected from the group consisting of adenine, guanine, thymine, cytosine, uracyl, 5,6 dihydrouracyl, 1-methyluracyl, 3-methyluracyl, 5-hydroxymethyluracyl, 2- thiouracyl, N⁴-acetylcytosine, 3-methylcytosine, 5-methylcytosine, 5- hydroxymethylcytosine, 1-methyladenine, 2-methyladenine, 7-methyladenine, N⁶-methlyl adenine, N⁶, N⁶-dimethyladenine, N⁶-(Δ^2 -isopentenyl)adenine, 1-methylguanine, 7-methylguanine, N²-methylguanine, and N², N²-dimethylguanine.

8. (currently amended) The derivative according to Claim 1, characterized in that said heterocyclic compound is ~~chosen from between~~ selected from the group consisting of adenine, guanine, thymine, and cytosine.
9. (previously presented) The derivative according to Claim 1, characterized in that said bond of a ionic type is obtained between said acid and at least two of said heterocyclic compounds that are the same as or different from one another.
10. (previously presented) The derivative according to Claim 1, characterized in that it is guanine hyaluronate.
11. (previously presented) The derivative according to Claim 1, characterized in that it is adenine hyaluronate.
12. (currently amended) The derivative according to Claim 1, characterized in that it is associated [[to]] with at least one ~~different~~ organic compound.
13. (currently amended) The derivative according to Claim 12, characterized in that said organic compound is ~~chosen from between~~ selected from the group consisting of natural amino acids, their oligomers and polymers ~~(peptides)~~.
14. (original) The derivative according to Claim 13, characterized in that it is guanine hyaluronate, polylysine.
15. (original) The derivative according to Claim 13, characterized in that it is adenine hyaluronate, polylysine.
16. (original) The derivative according to Claim 1, characterized in that it is cross-linked.

17. (original) The derivative according to Claim 16, characterized in that said cross-linking involves at least one hydroxyl group and/or at least one carboxyl group present on said hyaluronic acid.

18. (original) The derivative according to Claim 16, characterized in that said cross-linking is obtained with phosgene.

19. (currently amended) A process for the preparation of a derivative from between hyaluronic acid and at least one heterocyclic compound according to Claim 1, characterized in that hyaluronic acid or a salt thereof ~~is set to react~~ reacts with at least one heterocyclic compound in free or salified form.

20. (currently amended) A ~~[[The]]~~ process for the preparation of a derivative formed between hyaluronic acid and at least one heterocyclic compound according to Claim 12, characterized in that said derivative ~~of hyaluronic acid or a salt thereof is set to react~~ reacts with at least one organic compound in free or salified form.

21. (currently amended) A method of using ~~Use of~~ a derivative according to Claim 1, characterized in that said derivative is used as a ~~in the cosmetic field~~.

22. (currently amended) A method of using ~~Use of~~ a derivative according to Claim 1, characterized in that said derivative is used as a ~~in the pharmaceutical field~~.

23. (original) Cosmetic or pharmaceutical compositions comprising the compounds referred to in Claim 1.

24. (original) Cosmetic or pharmaceutical compositions comprising the compounds referred to in Claim 12.

25. (currently amended) A method of using ~~Use of~~ the compositions referred to in Claim 23, characterized in that said derivative is used as a ~~in the~~ cosmetic and/or pharmaceutical ~~field~~.

26. (new) A method of using the compositions referred to in Claim 24, characterized in that said derivative is used as a cosmetic and/or pharmaceutical.

27. (new) The derivative according to Claim 12, characterized in that said organic compound is a peptide.